Date Title Description PDF
15 Mar 2022 On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
14 Mar 2022 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
23 Feb 2022 On business and financial situation The Company releases the press release related to the full year 2021 financial results Download
23 Feb 2022 On business and financial situation The Company releases the full year 2021 financial results presentation Download
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download

Pages

Date Title Description PDF
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download
07 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 Download
31 Jan 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 Download

Pages

Date Title Description PDF
05 Jul 2019 R&D: new licenses, patents and registered trademarks ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. Download
02 Jul 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the second quarter of 2019 Download
26 Jun 2019 Información sobre dividendos The Company informs about the dividends payment Download
12 Jun 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its General Shareholders Meeting Download
08 May 2019 Convocatorias y acuerdos de Juntas y Asambleas generales ROVI releases the information related to its 2019 General Shareholders Meeting Download

Pages